Department of Endocrine and Digestive Surgery, Sorbonne Université, Hospital Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France.
Duke University School of Medicine, Durham, North Carolina, USA.
Br J Surg. 2019 Jun;106(7):889-897. doi: 10.1002/bjs.11145. Epub 2019 Apr 23.
The AJCC/UICC classification is widely used for predicting survival in papillary thyroid cancer (PTC), but has not been evaluated as a predictor of recurrence. The hypothesis of this study was that the eighth edition of the AJCC system can be used in this novel way.
All patients in the study underwent surgery for PTC at a high-volume endocrine surgery centre in France between 1985 and 2015. The seventh and eighth editions of the AJCC/UICC staging system for PTC were employed to predict recurrence and disease-specific survival using the Kaplan-Meier and log rank tests.
Among 4124 patients (79·7 per cent female), median age was 50 (i.q.r. 38-60) years; 3906 patients (94·7 per cent) underwent total thyroidectomy, with lymph node dissection in 2495 (60·5 per cent). The eighth edition of the AJCC/UICC staging system placed 91·8, 7·1, 0·4 and 0·7 per cent of patients in stages I-IV respectively. After reclassifying patients from the seventh to the eighth AJCC/UICC edition, the disease was downstaged in 23·8 per cent. Over a median follow-up of 7 years, 260 patients (6·4 per cent) developed recurrent disease, including 5·2 per cent of patients with stage I, 19·6 per cent with stage II, 59 per cent with stage III and 50 per cent with stage IV disease, according to the eighth edition. The eighth edition was a better predictor of recurrence than the seventh edition.
The eighth edition of the AJCC/UICC staging system appears to be a novel tool for predicting PTC recurrence, which is a meaningful outcome for this indolent disease. The eighth edition can be used to risk-stratify patients, keeping in mind that other molecular and pathological predictive factors must be integrated into the assessment of recurrence risk.
AJCC/UICC 分类被广泛用于预测甲状腺乳头状癌(PTC)的生存情况,但尚未评估其作为复发预测指标的能力。本研究的假设是,第八版 AJCC 系统可以以这种新颖的方式使用。
所有患者均于 1985 年至 2015 年在法国一家高容量内分泌外科中心接受 PTC 手术。使用 Kaplan-Meier 和对数秩检验,采用第七版和第八版 AJCC/UICC PTC 分期系统预测复发和疾病特异性生存。
在 4124 例患者(79.7%为女性)中,中位年龄为 50(IQR 38-60)岁;3906 例(94.7%)接受了全甲状腺切除术,其中 2495 例(60.5%)行淋巴结清扫术。第八版 AJCC/UICC 分期系统将 91.8%、7.1%、0.4%和 0.7%的患者分别归入 I-IV 期。将患者从第七版 AJCC/UICC 分期重新分类至第八版后,23.8%的患者分期降级。中位随访 7 年后,260 例(6.4%)患者发生复发病例,根据第八版 AJCC/UICC 分期,I 期患者中 5.2%、II 期患者中 19.6%、III 期患者中 59%、IV 期患者中 50%发生复发。第八版 AJCC/UICC 分期系统比第七版 AJCC/UICC 分期系统更能预测复发。
第八版 AJCC/UICC 分期系统似乎是预测 PTC 复发的一种新工具,这对于这种惰性疾病具有重要意义。可以使用第八版 AJCC/UICC 分期系统对患者进行风险分层,但需牢记,其他分子和病理预测因素必须纳入复发风险评估。